As a first step in our study of structure-function relationships among primate and nonprimate growth hormones, human growth hormone (hGH) was subjected to the limited digestive activity of human plasmin. The lyophilized whole digest, containing less than 2% of unchanged hormone, had an average of 2.3 new amino-terminal groups per mole. The digest had the same potency as the native hormone (a) in causing weight gain in hypophysectomized rats; (b) in stimulating somatomedin production in hypophysectomized rats; (c) in stimulating upake of [ 3 H]leucine into isolated diaphragm of hypophysectomized rats; (d) in accelerating transport of [ 14 C]a-aminoisobutyric acid into isolated diaphragm of hypophysectomized rats; (e) in stimulating uptake of [3-0-methyl-14 C]glucose by isolated adipose tissue of hypophysectomized rats; (f) in accelerating conversion of [ 14 C]glucose to 14 CO 2 by isolated epididymal adipose tissue of hypophysectomized rats. The digest also caused glucosuria in partially pancreatectomized rats treated with dexamethasone.
INTRODUCTION
The study of the effect of proteolytic enzymes on the activity of growth hormone is important for both fundamental and practical reasons. The identification of the minimum structural requirements for activity may improve understanding of the mechanism of action of the hormone, but it may also reveal a structure common to the growth hormones of all species, opening the way to relief of the scarcity of human growth hormone (hGH)' either by synthesis of the active residue or by its production from ample supplies of the growth hormone of ox, sheep, or pig. An early attempt to achieve this goal was made by Li, Papkoff, Fonss-Bech, and Condliffe (1), who showed that limited digestion of bovine growth hormone (bGH) with chymotrypsin could be carried out without significant loss of activity in the tibia test in the hypophysectomized rat. The claim was made that these digests were active in man (2) , but this claim could not be substantiated (3) . The problem was taken up again by Elsair, Vairel, Gerbeaux, Dartois, and Royer (4) who introduced better control of the digestion by the use of the pancreatic trypsin inhibitor of Kunitz and Northrop. The product of 30-min digestion of bGH, retaining about 50% of its original activity in the rat by the weight gain test, was given in very large daily doses to a number of pituitary dwarfs. Digests that were inhibited with acid, as in the experiments of Li et al. (1) , ' Abbrezviations used in this paper: AAN, a-amino nitrogen; ACTH, adrenocorticotropin; AIB, a-aminoisobutyric acid; bGH, bovine growth hormone; BW, body weight; FFA, free fatty acid; hGH, human growth hormone; KRB, Krebs-Ringer bicarbonate buffer; KRBG, KRB containing glucose; 3-OMG, [3- were not effective, but the more carefully controlled and stabilized digests appeared to bring about some nitrogen retention and, less consistently, to cause an increase in plasma free fatty acids 4 h after injection. The whole digest was not well tolerated by the patients, and it was not further purified or characterized. Sonenberg et al. (5) in 1965 described partial digestion of bGH with trypsin; they used soy bean trypsin inhibitor to control the extent of digestion. The purification and characterization of the reaction products have been described in a series of papers (6) (7) (8) (9) (10) (11) (12) . Briefly digested bGH, in which 2-3 peptide bonds were cleaved, is completely active in the rat (tibia test), and in hypopituitary human subjects at doses of 12-100 mg/day causes nitrogen retention, free fatty acid mobilization and impaired glucose tolerance. The digest has been fractionated by gel filtration in 35% acetic acid, yielding a fragment of molecular weight 16,500 and a smaller polypeptide of molecular weight 5,000 containing no cystine. The two fragments account for the weight and the amino acid composition of the original hormone. Both peptides, alone and in combination, are active in the rat but are much less potent than the undigested hormone. The smaller peptide, given in large doses to two pituitary dwarfs, induced some nitrogen retention and had a marked anti-insulin effect. This peptide is homologous in sequence with peptide 95-134 of human growth hormone (12) .
Interest in plasmin as an alternative enzyme to trypsin for the partial digestion of growth hormone arises from the report of Ellis, Nuenke, and Grindeland (13) that the proteinase contaminating bovine, ovine, porcine, and human growth hormone preparations and responsible at least in part for the electrophoretic heterogeneity of the products is plasmin. The properties of the contaminating enzyme are similar to those of plasmin in respect to activation by urokinase and inhibition by pancreatic trypsin inhibitor, soy bean trypsin inhibitor, benzamidine, and aminobenzamidine. Both the contaminating proteinase and plasmin hydrolyze arginyl and lysyl bonds in synthetic peptides and thus resemble trypsin in substrate specificity. The effects of human or bovine plasmin on bovine or rat growth hormone are similar to those of the contaminating proteinase: only a limited proportion of the arginyl and lysyl bonds are cleaved, and the resulting digests are equipotent with the native hormone. New amino-terminal groups and components more acidic than the precursor molecule appear during incubation of proteinase-containing bovine growth hormone (14, 15) . The more acidic components of such bovine growth hormone preparations have been isolated by Reusser (16) and by Free and Sonenberg (6) and shown to be biologically active. In our experience with incubated, proteinasecontaining hGH, the more acidic components, separated with DEAE-cellulose chromatography, are at least as active as the starting material (17) .
These observations have encouraged us to undertake a systematic study of the effects of human plasmin on hGH, with the ultimate objective of defining the minimum biologically active portion of the molecule. This paper describes preparation of digests of highly purified hGH with human plasmin and assay of the resulting digests for a variety of in vitro and in vivo activities in rat and man.
METHODS
Digestion of hGH with plasmin. Human plasmin was purchased from KABI, Stockholm, Sweden. Purified hGH was prepared as described previously (18, 19) . Most preparations of hGH contain multiple active components (20) . The least acidic component (Type A) is believed to be native hGH, and the more acidic components are thought to be generated from the native molecule by deamidation and/ or enzyme degradation. In this study preliminary observations were made on preparations in which the second least acidic component (Type B) was concentrated, but most of the work was done with preparations in which type A was the major and type B the minor component. The growth hormone potencies of homogeneous types A and B are identical.
The following method describes digestion of 100 mg hGH with plasmin, but it is applicable to 25-500 mg samples. The hormone was dissolved in 10 ml of 0.57 (wt/vol) ammonium bicarbonate, and 0.4 ml of human plasmin solution (10 mg/ml in 0.001 N HCl) was added. The mixture was incubated at 370 for 24 h and was then lyophilized.
Quantitative analysis for the appearance of new amino groups during digestion was carried out by reaction of samples of the digest with trinitrobenzenesulfonic acid under conditions described previously (21) . Phenylalanine was used as the standard. Disc electrophoresis of the digests was carried out on polyacrylamide gels as described by Ornstein (22) .
Assays for metabolic activity in animals. A variety of in vivo and in vitro tests were used to assay the metabolic properties of the digests of hGH in animals. The weight gain test quantitatively measures the potency of the digests relative to a growth, hormone standard, while the other assays provide only semi-quantitative estimates. However, these tests indicate whether a particular biological property of the hormone has been retained or lost following cleavage of the molecule with plasmin.
The ability of the digests to promote growth in hypophysectomized rats (Charles River Breeding Labs, Inc., Wilmington, Mass.) was measured by the 9-day weight gain test performed as previously described (18 (24) . After incubation, the cartilages were boiled for 5 min and washed overnight in running water. They were trimmed of extraneous tissue, and the portion of the cartilage within 6 mm of the costochondral junction was discarded (25) . The cartilages were then digested with 70% formic acid, and the radioactivity and protein concentration of the digests were determined by previously described methods (26) . Results are expressed in terms of disintegrations per minute per milligram of cartilage protein.
Diabetogenic activity was assessed by the procedure of Bates and Garrison (27). Partially (80%) pancreatectomized female rats weighing approximately 150 g were placed in metabolism cages, and 24-h urine samples were tested for glucose with Clinitest (AAmes Co., Elkhart, Ind.). Those animals free of glucosuria for 5-7 days were then injected subcutaneously twice daily for 4 days with dexamethasone (15 Ag/day) and hGH or the digest in 0.9% NaCl. Controls received dexamethasone and 0.9% NaCl. 24 h urine samples were collected throughout the 4 day treatment period. Urinary glucose concentration of 0.25% or more was considered a diabetogenic response. In those rats that responded, glucosuria usually developed on the 3rd day of treatment, and urinary glucose was generally 1-2%.
The ability of the digests to stimulate the incorporation of [2H]leucine into the protein of the isolated rat diaphragm when added in vitro was tested as follows. Hypophysectomized female rats (60-80 g) were killed by cervical fracture, and intact hemidiaphragms were prepared.
These were washed for 30 min at 370 in 30 ml of KrebsRinger bicarbonate buffer, pH 7.4, containing 10 mM glucose (KRBG). Then the hemidiaphragms were transferred to flasks containing 10 ml KRBG, [3H]leucine (0.2 IhCi/ml; 0.05 mM) and hGH or digest where appropriate. The flasks were then gassed with 95% 02-5% C02, sealed and incubated at 37°with gentle shaking for 1 h. After incubation, the diaphragm muscle was dissected from the rib cage and homogenized immediately in 5 ml of 5% trichloroacetic acid (TCA). Total protein was isolated, and its radioactivity was measured by previously described methods (28) . The results are expressed as disintegrations per minute per milligram protein.
The digests were also tested for capacity to stimulate transport of the nonutilizable amino acid a-aminoisobutyric acid (AIB) into the isolated rat diaphragm when added in vitro. Intact hemidiaphragms were prepared from female hypophysectomized rats (60-80 g) and washed for 10 min in 25 ml KRBG. The tissues were then transferred to flasks containing 10 ml KRBG, [1-'4C]AIB (0.1 p.Ci/ml; 1 mM) and the test material where appropriate. The flasks were gassed with 95% O2-5% C02 and incubated at 370 with gentle shaking for 1 h. Then the diaphragm muscle was dissected from the rib cage, weighed and homogenized in 2 ml 5% TCA. Radioactivity in the TCA soluble fraction of the homogenate and in the incubation medium was measured, and the distribution ratio for [1"C] AIB was then calculated as described previously (29) . For these calculations, the volume of the extracellular space of the diaphragm was obtained by measuring the volume of distribution of [2H]inulin in the tissue under the conditions employed in the above experiments. The values used for the calculations were: controls = 19.5 ml/100 mg wet muscle; hGH = 16.4 ml/100 mg wet muscle; digest = 16.3 ml/100 mg wet muscle.
In vitro effects of the digests on sugar transport into the isolated rat diaphragm were detected by measuring the penetation of [3-0-methyl-'C glucose (3-OMG) into the muscle. Intact hemidiaphragms of female hypophysectomized rats (60-80 g) were prepared and washed for 10 min in 25 ml Krebs-Ringer bicarbonate buffer (KRB). They were then transferred to flasks containing 10 ml KRB and test material where appropriate. The flasks were then gassed with 95% 02-5%o C02, sealed and incubated with gentle shaking at 370 for 30 min. Then 3-OMG was added to the medium (0.1 /Ci/ml; 0.1 mM), and incubation was continued for an additional 30 min. Then the diaphragm muscle was dissected from the rib cage, weighed, and homogenized in 2 ml 5% TCA. Radioactivity in the TCA soluble fraction of the homogenate and in the incubation medium was measured, and the distribution ratio for 3-OMG was calculated as previously described (29) .
The in vitro capacity of the digests to stimulate the conversion of ['4C]glucose to "CO2 by isolated epididymal FIGURE 1 Disc gel electrophoretic patterns of undigested hGH (on the left) and the same preparation after digestion with plasmin (right). Direction of migration toward the anode at bottom. The starting material is the second major fraction obtained by DEAE-cellulose chromatography (17, 19) and contains a minor, more acidic component. Both components are more acidic after digestion with plasmin.
Only a trace of the original material can be seen.
adipose tissue of male hypophysectomized rats (90-120 g) was studied using the procedure described by Goodman (30) .
Tests for metabolic activity in man. Nine children and adolescents with growth hormone deficiency and two adults with limb-girdle muscular dystrophy served as test sub-;jects. These two classes of patient were selected because of their hyperresponsiveness to exogenous hGH, compared with normal individuals (31, 32) . Criteria for deficiency of growth hormone, adrenocorticotropin (ACTH), and thyroid-stimulating hormone (TSH) were as previously described (31) . Clinical data are summarized in Table I The potency of plasmin digests of hGH, as determined by the weight gain test in hypophysectomized rats, is shown in comparison with the potency of the native precursor hGH from which each digest was prepared. * 95% confidence limits. a 14-day metabolic balance study measuring the effect, after a 7-day control period, of 7 days' treatment with test material on balances of N, P, Na, and K on body weight (BW), on fasting concentrations of FFA and AAN, and on the oral glucose tolerance curve (31) . In both types of assay, the response of the patients to three doses of clinical grade hGH (National Pituitary Agency, lots A17 and B17, approximately 1 U/mg) were first measured. The doses were:
dose A = 0.0168 U/kg BWI; dose B = 0.053 U/kg BWi; dose C = 0.168 U/kg BWI. The response of the patients to 0.053 or 0.168 mg/kg BW1 of the plasmin digest was then determined. Two preparations of digest were examined: HS 605 and HMW600 (HS)A. 1-day assays were done at 3-4 day intervals during a single admission to the metabolic research unit. 14-day assays were done at intervals of 1-2 mo. For 3 or more days before a 1-day assay, the patient was fed a diet containing 35 kcal/kg BW and 1.5 g protein/ kg BW; fat and carbohydrate furnished about 40% and 45%, of calories, respectively.
On test days the patient was fasted until 2 p.m. Heparinized plasma was obtained at 8 a.m. (0 h) for analysis of FFA (33) and AAN (34) . The specified dose of test sub- stance, dissolved in 1 ml saline, or (as a control) 1 ml saline, was then injected intramuscularly. At 3 and 6 h, fasting plasma FFA and AAN concentrations were determined again. The 14-day assay, which was preceded by 3 days' equilibration to the metabolic diet, consisted of a 7-day control period followed by a 7-day experimental periol (31) . The diet has been described before (31 BWi X 10-'). In addition, fasting plasma FFA and AAN were measured on days 5, 6, and 7 of both control and experimental periods, and the average change in these two concentrations between control and experimental periods was calculated. On the day before the equilibration period and on the day after the last injection of test substance,
In Vitro Effects of hGH and On disc electrophoresis, the digestion product of hGH was found to move faster toward the anode than the native hormone, but there was no striking change in the pattern of bands (Fig. 1) . A very fast diffuse band of unknown significance was sometimes seen. Type A or B hGH was not visible in the electropherogram of the plasmin digest, indicating that less than 2% of the digest consisted of uncleaved hormone. Six different plasmin digests of hGH were tested for the ability to stimulate growth in hypophysectomized rats in the 9-day weight gain assay. As can be seen in Table II , the digests generally retained full growth promoting potency when compared to precursor hGH.
The experiments summarized in Table III indicate that the plasmin digest of hGH also retained the ability of the native hormone to stimulate [3H]thymidine incorporation into the DNA of costal cartilage of hypophysectomized rats. The dose-response relationship for the plasmin digest was not characterized in detail, but since a dose of 2.5 Fg/day of native hGH usually produced only a threshold response in this test system, the data suggest that plasmin digestion probably has little or no effect on the ability of the molecule to stimulate thymidine incorporation into cartilage.
Digestion of hGH with plasmin also did not abolish its diabetogenic activity in 80% pancreatectomized-dexamethasone treated rats (Table IV) . However, the finding that a dose of 0.1 mg/day of the plasmin digest was not nearly as effective as an equivalent dose of native hGH in producing glucosuria in these animals suggests that the digest may have reduced diabetogenic potency in the rat.
Compared with native hGH, the plasmin digest was fully active in stimulating incorporation of labeled leucine into protein of the isolated diaphragm of the hypophysectomized rat. The concentration of hGH producing a threshold response in this test system was 2.5 .sg/ml of medium, and this concentration of the plasmin digest also produced a significant response (Table V) .
The digest was also fully active in vitro in stimulating amino acid transport and sugar transport into the isolated diaphragm of the hypophysectomized rat. The in vitro stimulatory effects of hGH and the digest on transport of AIB and 3-OMG into the diaphragm are summarized in Tables VI and VII, respectively. The experiments shown in Table VIII indicate that the digest, when added in vitro, also retained the ability to stimulate glucose utilization in isolated epididymal adipose tissue of the hypophysectomized rat. The concentration-response data suggest that, on a weight basis, the digest may be somewhat less potent that the native hormone in this test system. To assess the metabolic activity of the plasmin digest of hGH in man, 14-day assays were performed on eight subjects, and 1-day assays were carried out on four subjects. Table IX summarizes the 14-day experiments. Native hGH caused a significant (P < 0.05) retention of N at doses A, B, and C in zero, five, and eight individuals, respectively. Significant effects on P, Na, and K balance occurred with less regularity: dose A was ineffective in three trials; dose B caused significant P, Na, and K retention in only zero, one, and one of eight subjects; dose C stimulated retention of these elements in four, six, and three of eight persons, respectively. Weight gain also occurred.2 Ratios of AN, ANa, and AK (36) showed about one-half the weight gain to represent protoplasm and about one-half extracellular fluid. Dose C of hGH caused a significant (P < 0.05) reduction in fasting plasma AAN at days 5-7 of the 7-day course of treatment in each of three subjects but did not alter fasting FFA level significantly. Dose B lowered AAN significantly in one of three trials and dose A in none of three trials. Dose C reduced glucose tolerance in two of three patients examined for this response (Fig. 2) .
The two preparations of the plasmin digest tested in these subjects reproduced all of the effects of the intact 'P value could not be estimated for ABW in response to hGH, since this response was calculated as the change in BW over a 7-day (Table IX) . Significant effects in AN, AP, ANa, and AK occurred in five, two, three, and three out of five trials, respectively. In one patient (case 11) examined in this respect, 0.168 mg/kg BW"' of digest HS 605 caused a reduction in glucose tolerance similar to that produced in the same patient by dose C of hGH. Digest HMW600 (HS)A tested in three individuals was generally more potent than HS 605 (Table IX) . At the 0.053 and 0.168 mg/kg BW81' doses, this preparation caused retention of N, P, Na, K, and weight gain to a slightly greater extent than doses B and C of hGH, respectively. The 0.053 mg/kg BW3'/ dose caused significant retention of N, P, Na, and K in three, zero, zero, and zero subjects. At 0.168 mg/kg BW3'4, significant retention occurred in three, two, three, and three individuals. Both doses caused significant reduction in plasma AAN but did not alter FFA concentration. In cases 1 and 2, digest HMW600 (HS)A at the 0.168 mg/kg BW"' dose reduced glucose tolerance to about the same extent as dose C of hGH (Fig. 2) . In case 4, despite a brisk anabolic response to these doses of HMW600 (HS)A and hGH (Table IX) , glucose tolerance remained unchanged (Fig. 2) .
When the 1-day assay was employed in four subjects with GH-deficiency dose C of hGH lowered plasma AAN and increased plasma FFA significantly (P < 0.05); dose B affected only FFA (Table X) . Plasmin G-50 reveals that the action of the enzyme is mainly to set free a hexapeptide corresponding to residues 135-140 in native hGH. This small basic peptide would not necessarily appear in the gel electrophoretic pattern, but it would account for the greater anodal mobility of the residual major component and for the absence of new components in the electrophoretic pattern.
The plasmin digests of hGH retained all the metabolic actions of the native hormone in the rat: (a) to promote growth in hypophysectomized rats, (b) to stimulate thymidine incorporation into costal cartilage of hypophysectomized rats, (c) to cause glucosuria in 80% pancreatectomized-dexamethasone treated rats, (d) to stimulate protein synthesis in isolated diaphragms of hypophysectomized rats when added in vitro, (e) to stimulate amino acid transport and sugar transport into isolated diaphragms from hypophysectomized rats when added in vitro, and (f) to stimulate in vitro glucose utilization by isolated adipose tissue of hypophysectomized rats. It was of interest to examine the effects of the digests in this battery of assays that reflect the anabolic, diabetogenic, and insulin-like properties of hGH, because of the possibility that cleavage of the hormone molecule with plasmin might result in the loss of one or more of these activities. In previous studies (26) of the effects of cleavage of hGH and porcine growth hormone with cyanogen bromide, we found that the large fragment (corresponding approximately to the amino terminal 2/3 of the hormone) produced by this cleavage retained the ability to stimulate protein synthesis in liver and muscle tissue and the insulin-like property of the native hormone but lost the capacity to promote growth or stimulate thymidine incorporation into rat costal cartilage. In contrast, the present study shows that cleavage of hGH with plasmin does not dissociate the various metabolic properties of the intact hormone molecule. Furthermore the digests showed little or no reduction in potency in the various animal assays. In this regard, it should be (37) .
The experiments in Tables IX and X showed the plasmin digests also to be active in a variety of metabolic assays in human subjects, thus establishing that cleavage of the hGH molecule with plasmin does not substantially alter its properties in humans. One of the digests tested in human subjects, HS 605, was somewhat less active than the other, HMW600 (HS)A. In this connection, it is of interest that HS 605 also appeared to be less active than the precursor hGH from which it was made in the weight gain test in hypophysectomized rats (see Table  II ).
These experiments prove that the entire hGH sequence is not required for full anabolic potency in both the rat and man. The fully active plasmin digest becomes a useful starting material in searching for the minimum structural requirement for growth-promoting activity in man. The next step will be isolation of the active fragment in the plasmin digest and determination of its structure, followed by further fragmentation of this derivative and assay of its subunits.
